U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07459790) titled 'The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's Lesions' on Jan. 12.
Brief Summary: To evaluate the efficacy and safety of Neovasculgen in interstitial cystitis with Hunner's lesions to reduce cicatricial changes in the bladder caused by electrocoagulation and to prevent secondary bladder shrinkage with a decrease in its volume.
Study Start Date: Dec. 29, 2023
Study Type: INTERVENTIONAL
Condition:
IC
Hunner Type Interstitial Cystitis
Bladder Pain Syndrome
Intervention:
DRUG: Neovasculgen(R)
The bladder is hydro-bougienated, Hunner's lesions are identified, ...